Riskpilot← Back to searchSign inGet full accessClinical-Microbiomics A/S
A/SActiveCVR 37230634Fruebjergvej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 201533 employees
Revenue 2024
DKK 548K
-69% vs 2023
EBITDA margin
-641.2%
-119% vs 2023
Equity ratio
96.0%
Financial strength
Net profit 2024
DKK -4,3M
-122% vs 2023
| Revenue | DKK 548K | -69% |
| EBITDA | DKK -3,5M | -119% |
| Net profit | DKK -4,3M | -122% |
| Total assets | DKK 91,7M | +2% |
| Equity | DKK 88M | +2% |
| Employees | 33 | — |
Legal name
Clinical-Microbiomics A/S
CVR number
37230634
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. november 2015
Share capital
DKK 2.126.111
Employees
33 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og et bestyrelsesmedlem eller af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at drive kontraktsforskning inden for bioteknologi samt hermed beslægtede aktiviteter.
Address
Fruebjergvej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.292 | 1.422 | 8.507 | 13.163 | 17.024 | 16.769 | 18.987 | 1.779 | 548 |
| Staff expenses | -3.718 | -5.999 | -8.525 | -11.979 | -15.621 | -16.806 | -23.078 | -3.382 | -4.062 |
| EBITDA | -5.010 | -4.578 | -18 | 1.184 | 1.403 | -37 | -4.091 | -1.603 | -3.514 |
| Depreciation & amort. | -46 | -141 | -167 | -202 | -193 | -1.331 | -1.503 | -378 | -632 |
| EBIT | -5.055 | -4.719 | -185 | 983 | 1.210 | -1.368 | -5.594 | -1.981 | -4.146 |
| Net financials | -211 | -729 | -644 | -833 | -623 | -1.182 | -1.625 | -106 | -217 |
| Profit before tax | -5.266 | -5.447 | -830 | 149 | 587 | -2.550 | -7.218 | -2.087 | -4.363 |
| Tax | -1.130 | -1.070 | -347 | 42 | -229 | -827 | -310 | -136 | -35 |
| Net profit | -4.136 | -4.377 | -483 | 107 | 816 | -1.723 | -6.909 | -1.951 | -4.328 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7.496 | 3.737 | 6.292 | 11.539 | 12.543 | 28.266 | 141.635 | 90.236 | 91.711 |
| Equity | 607 | -3.771 | -4.254 | -4.147 | -3.330 | 2.826 | 119.543 | 86.290 | 88.032 |
| Long-term debt | 6.000 | 5.702 | 4.413 | 5.069 | 6.678 | 8.173 | 8.190 | 737 | 872 |
| Short-term debt | 889 | 1.806 | 6.133 | 10.616 | 9.195 | 17.268 | 13.902 | 3.209 | 2.807 |
| Total debt | 6.889 | 7.508 | 10.545 | 15.685 | 15.873 | 25.440 | 22.092 | 3.946 | 3.679 |
EBITDA margin
-641.2%
This company
15.8%
Market median
-4158% vs market
20162024
Equity ratio
96.0%
This company
38.2%
Market median
+151% vs market
20162024
Return on equity
-4.9%
This company
18.4%
Market median
-127% vs market
20162024
Net profit margin
-789.8%
This company
8.1%
Market median
-9851% vs market
20162024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20162024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-11-02 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RV Management | Management | 2015 | — | — |
LM Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
AC Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
MA Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
OS | Chairman | 2015 | — | — |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2023 | |
MANJIN ApS | Company | 5.0% | 5.0% | 2023 |
VENDLER ApS | Company | 5.0% | 5.0% | 2023 |
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2022 | |
OD Clinical Holding ApS | Company | 33.3% | 33.3% | 2016 |
TLC HOLDING ApS | Company | 5.0% | 5.0% | 2022 |
Clinical-Microbiomics A/S | Company | 10.0% | 10.0% | 2016 |
TAL Invest ApS | Company | 5.0% | 5.0% | 2022 |
REINHOLDT ENGINEERING ApS | Company | 5.0% | 5.0% | 2022 |
Verde Family Holding ApS | Company | 5.0% | 5.0% | 2022 |
ADSIDIUS ApS | Company | 5.0% | 5.0% | 2023 |
BIRKEHEGNET 13 HOLDING ApS | Company | 5.0% | 5.0% | 2022 |
DACCO INVEST ApS | Company | 5.0% | 5.0% | 2022 |
Pinnacle Holding ApS | Company | 15.0% | 15.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MANJIN ApS
Clinical-Microbiomics A/S Board members of Clinical-Microbiomics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rasmus Vendler Toft-Kehler | Management | 0 companies |
| Lone Merete Veng | Chief Executive Officer | 0 companies |
| Anders Christian Neto de Sousa Grøn | Chief Executive Officer | 0 companies |
| Martin Andreas Santini | Chief Executive Officer | 0 companies |
| Torben Thomasen | Board of Directors | 0 companies |
| Nathan Allen Ledeboer | Board of Directors | 0 companies |
| Bruce Harvey Grant | Board of Directors | 0 companies |
| Ole Skov | Chairman | 0 companies |
| Henrik Dalbøge | Board of Directors | 0 companies |
| Isabelle Valerie de Cremoux | Board of Directors | 0 companies |
| Thomas Alsbjerg | Board of Directors | 0 companies |
| Manoj Nirmal Dadlani | Chairman | 0 companies |
| Caroline Popper | Board of Directors | 0 companies |
| Dennis Landbo Nielsen | Board of Directors | 0 companies |
| Morten Otto Alexander Sommer | Board of Directors | 0 companies |
| Morten Asser Karsdal | Board of Directors | 0 companies |